Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies

• Published in: Clinical & translational oncology 2006-01, Vol.8 (1), p.50-53
• Main Authors: Puente Vázquez, Javier, López-Tarruella Cobo, Sara, García-Sáenz, José A, Casado Herráez, Antonio, Moreno Antón, Fernando, Sampedro Gimeno, Teresa, Bueno Muiño, Coralia, Grande Pulido, Enrique, Martín Jiménez, Miguel, Díaz-Rubio, Eduardo
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma - radiotherapy; Adenocarcinoma - secondary; Adenocarcinoma - surgery; Adult; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - epidemiology; Brain Neoplasms - radiotherapy; Brain Neoplasms - secondary; Brain Neoplasms - surgery; Breast Neoplasms - chemistry; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Carcinoma - chemistry; Carcinoma - drug therapy; Carcinoma - epidemiology; Carcinoma - secondary; Cranial Irradiation; Disease Progression; Female; Humans; Incidence; Middle Aged; Neoplasm Proteins - analysis; Neoplasm Proteins - antagonists & inhibitors; Receptor, Epidermal Growth Factor - analysis; Receptor, Epidermal Growth Factor - antagonists & inhibitors; Receptor, ErbB-4; Retrospective Studies; Survival Analysis; Trastuzumab; Treatment Outcome
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-006-0095-8

CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies. We performed a descriptive analysis of our experience in this setting. 86 patients met the criteria (From Oct/99 to Oct/03). CNS progression occurred in 17 patients (19.5%). Mean age of CNS progression disease patients was 45.4 years while mean age for all the patients was 50.5 years. Response rate for the entire group of patients was: OR 39.7%; CB (OR + SD) 69%. Response rate to trastuzumab based-therapy was OR 82.4% and CB 88.2 at the time of CNS progression. Median time from the start of trastuzumab therapy up to the CNS progression was 10 months. OS was 23.4 weeks. The incidence of CNS involvement is high in young metastasic breast cancer women responding to trastuzumab-based therapies. This may lead to prophylactic cranial irradiation strategies or to the early detection in asymptomatic patients to improve surgery or radiosurgery results in these patients.